Avascular necrosis (AVN) is a serious complication of acute lymphoblastic leukaemia (ALL) therapy. Little is known of the scope and magnitude of this problem among adults with ALL. We analysed the incidence and risk factors for AVN in 1053 patients on the UKALLXII/ECOG2993 study. AVN affected 99 joints in 42 patients at a median of 2.2 years post-diagnosis, giving a crude incidence rate of 4.0%. Statistically significant risk factors for the development of AVN were age and treatment with chemotherapy. Patients receiving prolonged chemotherapy without stem cell transplant were at significantly greater risk of developing AVN than stem cell transplant recipients (Po0.00005). The actuarial incidence of AVN was 29% at 10 years in patients o20 years old compared to 8% at 10 years in those 420 years old; P ¼ 0.0004; odds ratio 0.28 (95% CI ¼ 0.14-0.56).
Introduction
Avascular necrosis (AVN) of the bone is a rare but serious complication of treatment for acute lymphoblastic leukaemia (ALL), usually related to corticosteroid use. [1] [2] [3] [4] [5] Its development, in many cases, results in significant pain and loss of function sometimes necessitating joint replacement. 1 The majority of reported cases of AVN following therapy for ALL are in children. Little is known about the magnitude and clinical spectrum of AVN in adult ALL patients. Differences in the dose intensity of chemotherapeutic drugs as well as frequent use of stem cell transplantation in the treatment of adult ALL suggest that the pattern and occurrence of bone morbidity in this patient group may be distinct. We determined the presentation, incidence of AVN and analysed risk factors for its development among 1053 UK adult patients with ALL aged 15-55 enrolled on the UKALLXII/ECOG2993 study between 1993 and 2004. The data presented herein represent the largest study of symptomatic AVN in adult ALL.
Patients and methods
Between 1993 and September 2004, 1088 consecutive patients aged over 15 (aged 20 from 2006) and less than 65 years (up to 55 years for those with Philadelphia-negative ALL) with newly diagnosed ALL were enrolled onto the MRC UKALL XII trial. Thirty-five patients were treated on an amended protocol for patients with Philadelphia-positive (Ph þ ) disease, which included imatinib and have been excluded from this study. The study was approved by the Ethics Committees of each treating centre and informed consent was obtained according to the Declaration of Helsinki Principles, as appropriate to regulations at the time. Cases of AVN were identified after review of annual follow-up forms. Since these forms did not specifically request data regarding AVN further details of each AVN case were obtained by questionnaire sent to the treating centre. In order to capture AVN events, which were not reported by annual assessment forms, listings were also sent to each treating centre of all their patients asking whether they had suffered AVN, along with a questionnaire asking for details of each AVN case. Treating physicians and/or trial co-ordinators were asked to complete the questionnaire and provide information following review of medical notes on symptoms, joint involvement, diagnostic investigations and surgical intervention. Additional data were obtained from the Clinical Trial Service Unit trial database.
Treatment protocol
All patients received a two-phase induction. Following which patients under 50 (55 if Philadelphia chromosome-positive) years of age who had an HLA compatible sibling were assigned to an allogeneic stem cell transplantation (allo-SCT) or matched unrelated donor transplant in the case of Ph þ patients. All other patients were randomized between an autologous transplant and standard consolidation/maintenance therapy. Details of transplant and chemotherapy protocols are published elsewhere. 6 
Corticosteroid dose
Prednisolone was administered orally during phase 1 induction at a dose of 60 mg m À2 on days 1-28; Dexamethasone 10 mg m À2 was administered orally on days 1-28 during the first cycle of consolidation. Those patients not receiving a transplant were administered prednisolone 60 mg m À2 orally for 5 days every 3 months for 12 months as part of maintenance therapy. Cumulative doses of prednisolone and dexamethasone for patients receiving chemotherapy alone according to protocol specifications was 2880 and 280 mg m
À2
, respectively. Autograft and allograft recipients received 1680 mg m À2 of prednisolone during induction therapy. Steroids were administered post-allo-transplant at the physicians discretion according to local protocols.
Statistical and analysis methods
To compare the incidence of AVN by initial patient and disease characteristics w 2 -tests were used. Actuarial incidence was calculated by the Kaplan-Meier method, censoring at death and loss to follow-up. Groups were compared using the logrank test. Risk factor analysis excluded one patient who developed AVN prior to auto-SCT. In order to account for a lower survival among older patients reducing the observed incidence of AVN, cumulative incidence was calculated by competing risk analysis to indicate the proportion of patients who experienced AVN by age group. Event-free survival (EFS) comparisons between groups were analysed by Cox regression, using the diagnosis of AVN as a time-dependent variable. Risk factor analysis excluded one patient who developed AVN prior to auto-SCT.
Results
We identified 42 cases of established AVN involving a total of 99 joints. Thirty-nine were reported on annual assessment and an additional three cases were identified from the 546 survey responses received. All cases were symptomatic presentations. At a median follow-up of 6.3 years (range 1 month to 12.3 years). the crude incidence rate was 4.0% (42/1053). Considering only the 546 patients for whom the survey form was returned, the crude incidence was 7.7% (42/546).
The characteristics of each AVN case including treatment received are listed in Table 1 . The majority of cases were multifocal (30/42 patients, 71%) and affected mainly the weight bearing bones (74%) with the hip joint followed by the shoulder joint the most frequently involved sites ( Table 2 ). The median number of joints affected by AVN was 2.4 (range 1-6). The median time from diagnosis of ALL to diagnosis of AVN was 2.2 years (range 1 month to 7.3 year). A considerable proportion (24 of 40 evaluable patients; 60%) of the cases occurred more than 2 years from start of ALL therapy. All identified cases of AVN occurred during or after primary therapy. In the total AVN population the most frequently used tests for diagnostic evaluation of AVN was magnetic resonance imaging (MRI) which was performed in 20 of the 37 (54%) evaluable cases either as the sole investigation (7/37, 19% evaluable patients) or in addition to plain film radiographs (13/37, 35% evaluable patients). Plain film radiographs were reported as the sole diagnostic investigation in nine cases.
Management of established AVN varied. A total of nine patients received conservative therapy, which included limited weight bearing and analgesia, and twenty-eight patients required surgical intervention. Joint replacement was required in 23 patients of which 13 were multiple replacements. A further two patients did not receive a planned joint replacement due to relapsed disease and another two patients were awaiting bilateral hip replacements at the time of this study. Other orthopaedic procedures for the treatment of AVN included decompression (four patients) and arthroscopic drilling (one patient). An assessment of morbidity following AVN at the last known follow-up was made in 31 cases, eight patients were considered to have no long-term disability, 14 were reported as having minor disability and nine major disabilities.
Risk factors for the occurrence of AVN were analysed and are shown in Table 3 . Therapy received was a significant risk factor for the occurrence of AVN with the majority of AVN cases (36/ 42) occurring among chemotherapy patients and only a small number among stem cell transplant recipients (logrank Po0.00005). The actuarial risk of AVN within the chemotherapy group was 11% at 3 years and 16% at 10 years. Within the . The actuarial risk of AVN, after censoring for death or loss to follow-up, was 17% at 3 years (29% at 10 years) in those aged less than 20 years compared to 7% at 3 years (8% at 10 years) in those aged 20 years or older (P ¼ 0.0004); odds ratio of 0.28 (95% CI ¼ 0.14-0.56) (Figure 1 ) As many patients die before AVN is seen, competing risk analysis was used to calculate the cumulative incidence rates, which were 12% at 3 years (17% at 10 years) in the under 20-years age group and 3% at 3 and 10 years in those aged more than 20 (Figure 2) .
The actuarial incidences of AVN in the over 20 years age groups were 11% (eight patients) in the 20-29 years age group, 3% (one patient) in the 30-39 years age group and 6% (four patients) in the X40 years age group.
A total of 22 of 381 males and 14 of 244 females in the chemotherapy-treated patients developed AVN. Gender did not significantly affect risk of AVN (male:female ratio 1:1), and the relative risk of AVN in the o20 versus 420-year age groups was not significantly different between males and females.
The median age for AVN patients was 18 years with no significant differences in the median age for AVN between males and females overall or in the less than 20 years age group.
The median time to AVN in the chemotherapy group was 26.5 months. The majority of AVN cases occurred during year 2 and 3 (23/36; 55%, respectively), five cases occurred during year 1 and the remaining eight patients developed AVN during or after year 3. The longest time to diagnosis of AVN was 88 months after starting ALL therapy.
A total of 15 patients developed AVN after completion of therapy, 15 during maintenance phase, 4 during or after consolidation, 1 during induction and 1 during intensification therapies.
The 5-year EFS was 27% for all 625 chemotherapy patients. To determine if there was a correlation between the occurrence of AVN and overall EFS, Cox regression analysis used the diagnosis of AVN as a time-dependent covariate. The results did not show any significant difference in EFS between the AVN cases and the others in the chemotherapy-treated group.
There were five episodes of AVN among patients following stem cell transplantation. Three patients developed AVN after allo-SCT and two after auto-SCT. The median time to 
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Figure 1 Actuarial incidence of AVN by age among chemotherapy patients.
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B Patel et al transplantation in these patients was 5.6 months (range 4.6-6.3) from start of ALL therapy. The EFS for the 298 and 110 patients in the allo-SCT and auto-SCT group was 51 and 37%, respectively. The actuarial 10-year incidence of AVN in the allo-SCT group and auto-SCT group was 1 and 2%, respectively. AVN occurred 22, 33 and 33 months following allo-SCT and 3 and 34 months after auto-SCT. All patients with AVN posttransplant were aged X20 with a median age of 30 years. (range 22-43). Of the three patients who developed AVN following allo-SCT, two were reported to have developed acute graftversus-host disease (aGVHD), one requiring the administration of high doses of prednisolone, none were reported to have developed chronic GVHD (cGVHD).
Discussion
This analysis represents the largest study of symptomatic AVN in adult ALL. Chemotherapy patients were at significant risk of developing AVN compared to transplant recipients. The far greater cumulative steroid dose in chemotherapy-treated patients probably explains this finding. However, it is likely, additional factors will be relevant in the minority of cases where AVN occurred very early during the treatment course where the cumulative steroid dose is low. In patients with ALL multiple factors are implicated in the pathogenesis of AVN, such as the malignancy itself, procoagulant states and cytotoxic drugs 7, 8 However, corticosteroids are considered the most important aetiological factor. Glucocorticoid therapy in animal models is associated with adipocyte hypertrophy in the bone marrow which can result in elevated intraosseous pressure followed by reduced intramedullary blood flow, marrow ischaemia and ultimately necrosis. 9, 10 Indeed, reduction of blood flow to the femoral head has been demonstrated in animals treated with short-term high-dose methylprednisolone.
11 Glucocorticoids can also cause direct toxicity to osteocyte cells. 12 In our study, age greatly influenced the risk of developing AVN in the chemotherapy group, with crude incidences of 15% in patients aged o20 years old and 3% in patients aged 420 years at diagnosis of ALL. Hence our study suggests that AVN is a toxicity that is relatively specific to young adults. Taken in conjunction with published reports of AVN in childhood ALL where the highest incidence of AVN is seen in older children, that is, those aged over 9 years 1,3 both the upper and lower age limit for maximum risk for AVN during therapy for ALL can now be defined.
Our findings support the proposed mechanism of corticosteroid-induced AVN in adolescents, which attributes physiological changes, such as epiphyseal closure and changes in circulating hormone levels in the maturing bones of adolescents more susceptible to steroid induced bony changes. 13, 14 As an increasing number of younger adults receive ALL treatment according to paediatric rather than adult protocols with the concomitant higher dose intensity of steroids, [15] [16] [17] [18] our study predicts that the incidence of AVN will increase. The reported frequency of osteonecrosis with MRI screening varies from 0 to 44% depending on the type of therapy administered. 19 However, radiographic evidence of AVN is not always associated with clinical sequelae. 20 Balanced against this is evidence that joint-sparing procedures are more likely to be successful in early-stage disease. 21, 22 Lipid-lowering drugs, hyperbaric oxygen in addition to limited weight bearing have been used in small patient numbers to prevent progression of early AVN with variable success. 23, 24 Ultimately, a better understanding of the natural history of AVN, the exact pathogenic mechanisms involved in discrete patient groups will pave the way for the development of successful treatment strategies in the management of established AVN.
Most AVN cases in our study occurred more than 2 years from start of ALL therapy. This finding is in contrast to the occurrence of AVN in childhood ALL, which occurs more often within the first 2 years of diagnosis. 1, 3 It is possible that the apparently later occurrence in our cohort results from the estimation of the time to AVN from diagnosis rather than from time of first symptoms. Despite this, the majority of cases still occurred late during or even after the cessation of ALL therapy. Hence we recommend maintaining a high index of suspicion for AVN during posttherapy follow-up.
Our analysis did not show improved EFS among AVN patients. However, previous studies in childhood ALL have indicated a trend towards this, which has been attributed to high-glucocorticoid sensitivities in certain individuals resulting in not only higher anti-leukaemic potency by steroid drugs but also increased effects on bone physiology. 1 The frequency of AVN following allo-SCT and auto-SCT was similar in our study, however published data suggest AVN is a more frequent complication after allo-SCT. 25 Although there are no specific data of AVN following SCT in patients with ALL, among long-term survivors after allogeneic bone marrow transplantation for a varying number of haematological diseases the incidence of AVN is estimated between 3.7 and 19%. 25 Chronic GVHD requiring long-term steroid therapy, prolonged immunosuppressive therapy, increasing age and total body irradiation are considered the main risk factors for AVN in these patients. 25 Small numbers of cases in our study did not allow adequate assessment of these risk factors in our patients. There are a number of limitations to our study. The incidence of AVN was determined retrospectively, thus the reported incidence of AVN may be an underestimate. This may be for several reasons. There were a number of centres, which did not respond to the questionnaire. It is also possible that a reporting bias towards more severe cases of AVN particularly those cases, which resulted in surgical intervention occurred and that less with significant cases, namely those managed conservatively or with transient episodes of AVN were underreported. In addition, awareness by medical staff of AVN as a complication of therapy may have been low, particularly in the early years of the trial.
The development of AVN following treatment for adult ALL is a rare but serious complication resulting in significant morbidity. As progress is being made in the treatment of ALL, an increasing awareness of the potential long-term toxicities of intensive therapies should also be considered when assessing the efficacy of treatment protocols and in refining components of these. In young adults with ALL the risk of AVN is significant, a consideration which should be borne in mind when evaluating potential treatment choices for this patient group. The purpose of our study was to characterize the scope of AVN in a previously unstudied group of patients thereby increase awareness of the diagnosis of AVN among treating physicians. Prospective studies on the value of screening for osteonecrosis and the utility of non-surgical treatments for established earlystage AVN and in the prevention of this serious complication are warranted.
